Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lamivudine
Drug ID BADD_D01242
Description A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Indications and Usage For the treatment of HIV infection and chronic hepatitis B (HBV).
Marketing Status approved; investigational
ATC Code J05AF05
DrugBank ID DB00709
KEGG ID D00353
MeSH ID D019259
PubChem ID 60825
TTD Drug ID D07TQV
NDC Product Code 65015-756; 49702-203; 60687-362; 53873-075; 49702-205; 69097-167; 42385-714; 52482-003; 70966-0036; 0173-0663; 65862-055; 60505-3252; 65862-026; 69097-166; 53873-073; 55773-0589; 68554-0043; 31722-001; 49702-204; 64380-710; 68554-0016; 31722-752; 31722-754; 50742-624; 60687-720; 64380-711; 68180-602; 53104-7677; 70159-001; 31722-753; 54838-566; 57237-274; 60429-354; 66993-478; 68180-603; 53104-7538; 65015-701; 67835-0017; 60505-3250; 0904-6583; 53873-074; 65862-577; 33342-001; 0173-0662; 60505-3251; 65862-259; 65862-025; 82245-0204; 33342-002; 50742-623; 60429-353
UNII 2T8Q726O95
Synonyms Lamivudine | 3TC | 2',3'-Dideoxy-3'-thiacytidine | 2',3' Dideoxy 3' thiacytidine | Epivir | Lamivudine, (2S-cis)-Isomer | BCH-189 | BCH 189 | BCH189 | GR-109714X | GR109714X
Chemical Information
Molecular Formula C8H11N3O3S
CAS Registry Number 134678-17-4
SMILES C1C(OC(S1)CO)N2C=CC(=NC2=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Liver function test abnormal13.03.04.030--Not Available
Liver transplant rejection12.02.03.011; 10.02.03.005; 09.01.08.0070.001518%Not Available
Loss of consciousness17.02.04.004--Not Available
Lung disorder22.02.07.0010.001012%Not Available
Lymphadenopathy01.09.01.002--Not Available
Lymphoma16.20.01.001; 01.12.01.0010.002024%Not Available
Malaise08.01.01.003--
Malignant melanoma16.03.01.001; 23.08.01.0010.002530%Not Available
Metabolic acidosis14.01.01.0030.002024%Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mood swings19.04.03.001--Not Available
Mouth ulceration07.05.06.004--Not Available
Movement disorder17.01.02.0100.002024%Not Available
Muscle atrophy17.05.03.004; 15.05.03.0030.002024%Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005--Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.004554%
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myocarditis02.04.03.0010.001012%
Myopathy15.05.05.0010.003036%Not Available
Myopathy toxic15.05.05.006; 12.03.01.0350.002530%Not Available
Myositis15.05.01.0010.001012%
Nasal congestion22.04.04.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Nephrolithiasis20.04.01.0020.001518%
Nephropathy toxic20.05.03.002; 12.03.01.0100.008804%Not Available
Nephrotic syndrome20.05.01.0020.001012%
Nervous system disorder17.02.10.0010.002024%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 13 Pages